Stockscreener 앱 받기
66.26
1.88%
1.22
전일 마감가:
$65.04
열려 있는:
$65.49
하루 거래량:
2.08M
Relative Volume:
1.10
시가총액:
$8.10B
수익:
$18.47M
순이익/손실:
$-589.53M
주가수익비율:
-12.60
EPS:
-5.26
순현금흐름:
$-399.80M
1주 성능:
+6.29%
1개월 성능:
+4.63%
6개월 성능:
+79.66%
1년 성능:
+59.20%
1일 변동 폭
$64.58
$67.54
1주일 범위
$61.58
$67.89
52주 변동 폭
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
66.26 | 7.95B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-12-18 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-07-30 | 재개 | Raymond James | Mkt Perform |
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Will Cytokinetics Incorporated stock outperform Nasdaq index2025 Macro Impact & AI Driven Price Forecasts - mfd.ru
Cytokinetics (CYTK) Valuation Check After MYQORZO Approval And Renewed Analyst Bullishness - Yahoo Finance
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026 - Bitget
Cytokinetics (CYTK) Is Up 5.2% After Aficamten Milestones And Probe News Has The Bull Case Changed? - Yahoo Finance
Cytokinetics, Incorporated (NASDAQ: CYTK) Long Term Investor Alert: Investigation of potential Wrongdoing - openPR.com
Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Boston Scientific (BSX) - The Globe and Mail
Cytokinetics announces recipients of its eighth annual communications grant program - marketscreener.com
Cytokinetics Announces Recipients Of Its Eighth Annual Communications Grant Program - TradingView
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program - The Manila Times
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aug Selloffs: Is Cytokinetics Incorporated a potential multi baggerJuly 2025 Setups & Weekly High Potential Alerts - baoquankhu1.vn
Bank Watch: Does Cytokinetics Incorporated offer margin of safetyJuly 2025 Momentum & Stepwise Trade Signal Implementation - baoquankhu1.vn
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Andrew Callos Sells 15,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Bank of America Securities Remains a Hold on Cytokinetics (CYTK) - The Globe and Mail
Surprises Report: Is Cytokinetics Incorporated stock a good pick for beginners2025 Support & Resistance & AI Enhanced Execution Alerts - baoquankhu1.vn
Cytokinetics stock maintains Buy rating at B.Riley amid strong CMI market - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire
Cytokinetics, Incorporated (CYTK): A Bull Case Theory - Finviz
Truist Financial Forecasts Strong Price Appreciation for Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Truist Raises Price Target on Cytokinetics to $92 From $84, Keeps Buy Rating - marketscreener.com
Truist Securities Raises Price Target for CYTK with Buy Rating | - GuruFocus
2026 Biotech Hot Picks: Top 7 Stocks to Watch | Truist Analysis - techi.com
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Play with a 41.55% Upside Potential - DirectorsTalk Interviews
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 886 Shares - MarketBeat
New Highs: Whats the RSI of Cytokinetics Incorporated stockQuarterly Market Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Lisanti Capital Growth LLC Acquires New Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Sells 444,464 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Will Cytokinetics Incorporated outperform its industry peersShort Setup & Stock Portfolio Risk Management - mfd.ru
J. Safra Sarasin Holding AG Sells 43,723 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cardiac Myosin Inhibitor Now Available for Treating Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Diagnostic and Interventional Cardiology
Halozyme buys a biotech startup; Cytokinetics launches heart drug - BioPharma Dive
Cytokinetics (CYTK) Receives Overweight Rating from Barclays, PT Set at $87 | CYTK Stock News - GuruFocus
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Barclays - MarketBeat
Cytokinetics, Olympic Medalist McLaughlin-Levrone team up for awareness for HCM - Yahoo Finance
CYTK: Cytokinetics Launches Myqorzo in the U.S. for Heart Condition - GuruFocus
Assessing Whether Cytokinetics (CYTK) Looks Undervalued After Recent Share Price Momentum - Yahoo Finance
How MYQORZO’s REMS‑Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors - Yahoo Finance
Truist Securities reiterates Buy rating on Cytokinetics stock at $84 target - Investing.com Canada
Cytokinetics launches first product, Myqorzo - The Pharma Letter
Analyst Upgrade: What is the long term forecast for Cytokinetics Incorporated stock2025 Price Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM) - MultiVu
Cytokinetics (CYTK) Launches HCM Awareness Campaign with Olympic Star - GuruFocus
Olympian Sydney McLaughlin-Levrone on hypertrophic cardiomyopathy at home - Stock Titan
Cytokinetics Announces U.S. Launch of MYQORZO™ (aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy - Quiver Quantitative
New heart drug MYQORZO reaches U.S. patients, but with strict safety rules - stocktitan.net
US FDA caps 2025 with December high of 27 drug approvals - BioWorld MedTech
Cytokinetics, Incorporated (CYTK) Stock Analysis: Uncovering a 41% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $95 - 富途资讯
Cytokinetics Board Faces Claims of Breach of Fiduciary Duty as Stock Plummets - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):